Loading…
Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.
Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.
In one line: A small Fosun-affiliated generics maker.
Moat: none (distribution). Commodity generics maker without a distinctive patented product line.
Headquarters: Shanghai, China · Employees: 9,697
Size Shanghai Shyndec Pharmaceutical (600420.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1488th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.29 on 6 Nov 2026.
Performance Over six months the shares fell 13.6%, against -4.2% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 13.1% over the last twelve months (peer median +10.9%); the operating margin is 6.2% (peer median 13.0%).
Valuation It trades at 13.2× forward earnings against a peer median of 27.9× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points above its cost of capital (5.1% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.03B | CN¥9.30B | CN¥10.9B | CN¥12.0B | CN¥12.9B |
| Revenue growth | — | -14% | -9% | -7% | — |
| Gross profit | CN¥2.81B | CN¥2.83B | CN¥4.05B | CN¥4.36B | CN¥4.67B |
| EBITDA | n/a | CN¥1.82B | CN¥2.30B | CN¥1.78B | CN¥1.69B |
| Net income | CN¥451M | CN¥942M | CN¥1.08B | CN¥692M | CN¥628M |
| Free cash flow | CN¥514M | CN¥1.47B | CN¥2.05B | CN¥1.39B | CN¥2.55B |
| Capital expenditure | CN¥201M | CN¥264M | CN¥220M | CN¥357M | CN¥307M |
| Total debt | CN¥1.33B | CN¥1.19B | CN¥1.69B | CN¥1.75B | CN¥3.86B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Shyndec Pharmaceutical 600420.SS | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600420.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.5% | +0.7% | 9th lowest of 21 |
| 6-month return | -13.6% | -4.2% | 6th lowest of 20 |
| Distance from 52-week high | -25.2% | -27.4% | 11th highest of 21 |
| Revenue growth (TTM) | -13.1% | +10.9% | 3rd lowest of 19 |
| Operating margin | 6.2% | 13.0% | 4th lowest of 19 |
| Forward P/E | 13.2× | 27.9× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.0% | 10.7% | 2nd least demanding of 13 |
| Growth delivered (Del g) | -5.6% | +10.4% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | -0.4 pp | -4.0 pp | 6th most demanding of 13 |
| ROIC minus cost of capital | +0.2 pp | +1.7 pp | 8th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |